The Asia-Pacific gastrointestinal drugs market is expected to reach USD 14,868 Million by 2030 at 8.60% CAGR during the forecast period 2022-2030 The growth of the market is attributed to the increasing prevalence of GI disorders, such as peptic ulcers, inflammatory bowel disease (IBD), and gastroesophageal reflux disease (GERD), in the region. Additionally, the rising demand for proton pump...